OWCP has a excellent leadership team with industry wide recognized leaders guiding them. They are fully SEC compliant and have plans to uplist to NASDAQ. The stock seems to be undervalued at the moment; however, OWCP has a solid pipeline going for it with 8 patents including multiple delivery methods that could be licensed. OWCP recently announced in their most recent 8k that the results were “highly possible breakthrough” for their psoriosis cream. Shareholds and patients are awaiting exact efficacy results. Additionally, an IRB study on the cream was expanded for other illnesses. These should be annouced by OWCP soon. Overall the 8k was informative letting those following the company where they are in the cream development and that manufacturing/distribution, and revenue are expected to begin in Q2 2017. OWCP has already laid the ground work for global distribution of the product having announced multiple distribution contracts for North America and Europe. There is no liabilities and the company recently announced at the wallstreet conference in flordia earlier this month that it had enough funds for 2017 operations.